REGULATED INFORMATION

Publication relating to transparency notifications

Mont–Saint–Guibert (Belgium), December 2, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received two transparency notifications as detailed below.

Robert Taub / BMI Estate

On November 27, 2025, Nyxoah received a transparency notification from Robert Taub and related person BMI Estate. Based on the notification, Robert Taub (together with his controlled undertakings) holds 4,290,800 voting rights, consisting of 4,240,800 voting rights linked to securities and 50,000 equivalent financial instruments, representing 9.97% of the total number of voting rights on November 20, 2025 (43,026,460).

The notification dated November 27, 2025 contains the following information:

• Reason for the notification: passive crossing of a threshold
• Notification by: a parent undertaking or a controlling person
• Persons subject to the notification requirement:
  • Robert Taub
  • BMI Estate (with address at Avenue des Croix de Guerre 149 / 13, 1120 Brussels)
• Date on which the threshold was crossed: November 20, 2025
• Threshold that is crossed: 10%
• Denominator: 43,026,460
• Notified details:

• Full chain of controlled undertakings through which the holding is effectively held: Robelga SRL is 100% owned by BMI Estate (a partnership (société simple) without legal personality). Robert Taub has 100% usufruct and Robert Taub’s children have 100% bare ownership of BMI Estate.

Robert Taub / BMI Estate

On December 2, 2025, Nyxoah received a transparency notification from Robert Taub and related entity BMI Estate. Based on the notification, Robert Taub (together with his controlled undertakings) holds 4,360,800 voting rights, consisting of 4,310,800 voting rights linked to securities and 50,000 equivalent financial instruments, representing 10.14% of the total number of voting rights on December 1, 2025 (43,026,460).

The notification dated December 2, 2025 contains the following information:

• Reason for the notification: acquisition or disposal of voting securities or voting rights
• Notification by: a parent undertaking or a controlling person
• Persons subject to the notification requirement:
  • Robert Taub
  • BMI Estate (with address at Avenue des Croix de Guerre 149 / 13, 1120 Brussels)
• Date on which the threshold was crossed: December 1, 2025
• Threshold that is crossed: 10%
• Denominator: 43,026,460
• Notified details:

• Full chain of controlled undertakings through which the holding is effectively held: Robelga SRL is 100% owned by BMI Estate (a partnership (société simple) without legal personality). Robert Taub has 100% usufruct and Robert Taub’s children have 100% bare ownership of BMI Estate.

*

* *

Contact:
Nyxoah
John Landry, CFO
[email protected]

Attachment

• 2025 12 02 PR Transparency notification (Robert Taub) (ENG)

GLOBENEWSWIRE (Distribution ID 1001142526)

INFORMATION RÉGLEMENTÉE

Publication relative à des notifications de transparence

Mont–Saint–Guibert (Belgique), le 2 décembre 2025, 22:30h CET / 16:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nyxoah SA (Euronext Brussels/Nasdaq : NYXH) annonce qu’elle a reçu deux notifications de transparence comme détaillées ci–dessous.

Robert Taub / BMI Estate

Le 27 novembre 2025, Nyxoah a reçu une notification de transparence de Robert Taub et d’une personne liée, BMI Estate. Sur la base de la notification, Robert Taub (avec ses entreprises contrôlées) détient 4.290.800 droits de vote, soit 4.240.800 droits de vote attachés à des titres et 50.000 instruments financiers assimilés, représentant 9,97% du nombre total des droits de vote en date du 20 novembre 2025 (43.026.460).

La notification datée du 27 novembre 2025 contient les informations suivantes :

• Motif de la notification : franchissement de seuil passif
• Notification par : une entreprise mère ou une personne détenant le contrôle
• Personnes tenues à la notification :
  • Robert Taub
  • BMI Estate (avec adresse à Avenue des Croix de Guerre 149 / 13, 1120 Brussels)
• Date du dépassement de seuil : le 20 novembre 2025
• Seuil franchi : 10%
• Dénominateur : 43.026.460
• Détails de la notification :

• Chaine des entreprises contrôlées par l'intermédiaire desquelles la participation est effectivement détenue : Robelga SRL est 100% propriété de BMI Estate (société simple sans personnalité juridique). Robert Taub a 100% l'usufruit et les enfants de Robert Taub ont 100% la nue–propriété de BMI Estate.

Robert Taub / BMI Estate

Le 2 décembre 2025, Nyxoah a reçu une notification de transparence de Robert Taub et d’une personne liée, BMI Estate. Sur la base de la notification, Robert Taub (avec ses entreprises contrôlées) détient 4.360.800 droits de vote, soit 4.310.800 droits de vote attachés à des titres et 50.000 instruments financiers assimilés, représentant 10,14% du nombre total des droits de vote en date du 1^er décembre 2025 (43.026.460).

La notification datée du 2 décembre 2025 contient les informations suivantes :

• Motif de la notification : acquisition ou cession de titres conférant le droit de vote ou de droits de vote
• Notification par : une entreprise mère ou une personne détenant le contrôle
• Personnes tenues à la notification :
  • Robert Taub
  • BMI Estate (avec adresse à Avenue des Croix de Guerre 149 / 13, 1120 Brussels)
• Date du dépassement de seuil : le 1^er décembre 2025
• Seuil franchi : 10%
• Dénominateur : 43.026.460
• Détails de la notification :

• Chaine des entreprises contrôlées par l'intermédiaire desquelles la participation est effectivement détenue : Robelga SRL est 100% propriété de BMI Estate (société simple sans personnalité juridique). Robert Taub a 100% l'usufruit et les enfants de Robert Taub ont 100% la nue–propriété de BMI Estate.

*

* *

Contact:
Nyxoah
John Landry, CFO
[email protected]

Pièces jointes

• 2025 12 02 PR Transparency notification (Robert Taub) (FR)
• 2025 12 02 PR Transparency notification (Robert Taub) (FR)

GLOBENEWSWIRE (Distribution ID 1001142526)

Nyxoah to Participate in the Piper Sandler 37^th Annual Healthcare Conference

Mont–Saint–Guibert, Belgium – 27 November, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the management team will participate in a fireside chat at the Piper Sandler 37^th Annual Healthcare Conference on Thursday, Dec. 4, 2025. The fireside chat is scheduled at 1:30 p.m. (ET) the same day via webcast.

A live audio webcast of the presentation will be available online at the investor relations page of the Company’s website at investors.nyxoah.com.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription–only device.

Contact:

Nyxoah
John Landry
Chief Financial Officer
[email protected]

Rémi Renard
Chief Investor Relations & Corporate Communication Officer
[email protected]

Attachment

• ENGLISH_NYXH Piper Conf Advisory PR_2025

GLOBENEWSWIRE (Distribution ID 1001141443)

Nyxoah Participera à la Piper Sandler 37^th Annual Healthcare Conference

Mont–Saint–Guibert, Belgique – 27 novembre 2025, 22h05 CET / 16h05 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » ou la « Société ») une société de technologie médicale spécialisée dans le développement et la commercialisation de solutions innovantes pour le traitement de l'Apnée Obstructive du Sommeil (« AOS ») par neuromodulation, a annoncé aujourd'hui que son management participera à une discussion informelle lors de la Piper Sandler 37^th Annual Healthcare Conference, le jeudi 4 décembre 2025. La discussion informelle est prévue à 13h30 ET le même jour et sera diffusée en webcast.

Une webdiffusion audio en direct de la présentation sera disponible en ligne sur la page Relations avec les investisseurs du site web de la Société à l'adresse investors.nyxoah.com.

À propos de Nyxoah
Nyxoah opère dans le secteur des technologies médicales. Elle se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). La principale solution de Nyxoah est le système Genio^®, une thérapie de neurostimulation du nerf hypoglosse sans sonde et sans batterie qui a reçu le marquage CE, centrée sur le patient et destinée à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS), le trouble respiratoire du sommeil le plus courant au monde. Ce dernier est associé à un risque accru de mortalité et des comorbidités, dont les maladies cardiovasculaires. La visions de Nyxoah est que les patients souffrant de SAOS doivent pouvoir profiter de nuits réparatrices et vivre pleinement leur vie.

À la suite de la finalisation probante de l’étude BLAST OSA, le système Genio^® a reçu le marquage européen CE en 2019. Nyxoah a réalisé avec succès deux IPO : l’une sur Euronext Bruxelles en septembre 2020 et l’autre sur le NASDAQ en juillet 2021. Grâce aux résultats positifs de l'étude BETTER SLEEP, Nyxoah a reçu le marquage CE pour l’extension de ses indications thérapeutiques aux patients souffrant de collapsus concentrique complet (CCC), pour lesquels les thérapies concurrentes sont actuellement contre–indiquées. En outre, la Société a annoncé les résultats positifs de l'étude pivot DREAM IDE et l'obtention de l'autorisation de la FDA pour un sous–groupe de patients adultes atteints d'AOS modérée à sévère avec un IAH supérieur ou égal à 15 et inférieur ou égal à 65.

Pour plus d’informations, visitez www.nyxoah.com

Attention – marquage CE depuis 2019. Approuvé par la FDA en août 2025 en tant que dispositif disponible uniquement sur prescription médicale.

Contacts :

Nyxoah
John Landry, CFO
[email protected]

Rémi Renard
Chief Investor Relations & Corporate Communication Officer
[email protected]

Pièce jointe

• FRENCH_NYXH Piper Conf Advisory PR_2025

GLOBENEWSWIRE (Distribution ID 1001141443)

Nyxoah’s Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule

Assignment to New Technology APC 1580 is positive news for Nyxoah’s U.S. commercial rollout by strengthening hospital and ASC economics

Mont–Saint–Guibert, Belgium – November 26, 2025, 7:45 am CET / 1:45 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has finalized its CY2026 Hospital Outpatient Prospective Payment System (HOPPS) and Ambulatory Surgery Center (ASC) Rule. Within the final rule, CMS assigned CPT Code 64568, the code used for all Genio hypoglossal nerve stimulation (HGNS) implants, to New Technology Ambulatory Payment Classification (APC) 1580.

Effective January 1, 2026, Hospital Outpatient Department (HOPD) reimbursement for CPT 64568 will increase to approximately $45,000, a 48% rise compared to 2025. In addition, Ambulatory Surgery Centers (ASC) facility reimbursement will increase to $42,373, reflecting a 58% increase compared to 2025.

These updates apply uniformly to all procedures billed under CPT 64568, including Genio®, and strengthen the economic foundation supporting therapy adoption across U.S. hospital outpatient departments and ambulatory surgical centers. With CMS’ decision, Genio® enters 2026 with a stronger reimbursement framework that is expected to support broader adoption, increased procedural throughput, and expansion across Medicare–heavy institutions.

Genio®’s single–incision procedure is well suited for the ASC environment, and the significant increase in ASC facility payment creates new opportunities for therapy expansion and site–of–service diversification.

“CMS’ decision to significantly increase reimbursement for CPT 64568 reinforces the growing recognition of hypoglossal nerve stimulation as a high–value therapy for obstructive sleep apnea,” commented Olivier Taelman, Nyxoah's Chief Executive Officer.“ The new rates create a more favorable environment for expanding access to our Genio therapy across both outpatient hospitals and ASCs.”

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription–only device.

Forward–looking statements

Certain statements, beliefs and opinions in this press release are forward–looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward–looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward–looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20–F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward–looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward–looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward–looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward–looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward– looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward–looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward–looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward–looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah
John Landry, CFO
[email protected]

Rémi Renard
Chief Investor Relations & Corporate Communication Officer
[email protected]

Attachment

• ENGLISH_2026 CMS Final Payment Rule_FINAL

GLOBENEWSWIRE (Distribution ID 1001141004)

La Thérapie Genio® de Nyxoah Bénéficie d'une Augmentation Significative du Remboursement Medicare en 2026 en Vertu de la Règle Finale du CMS

L'attribution à l’APC “nouvelle technologie” 1580 donne un élan significatif au lancement commercial de Nyxoah aux États–Unis en renforçant la rentabilité des hôpitaux et des centres de chirurgie ambulatoire

Mont–Saint–Guibert, Belgique – 26 novembre 2025, 7h45 CET / 1h45 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » ou la « Société ») une société de technologie médicale spécialisée dans le développement et la commercialisation de solutions innovantes pour le traitement de l'Apnée Obstructive du Sommeil (« AOS ») par neuromodulation, a annoncé aujourd'hui que les Centres américains pour les services Medicare et Medicaid (Centers for Medicare & Medicaid Services – CMS) ont annoncé avoir finalisé leur règlement pour le système de paiement prospectif des soins hospitaliers ambulatoires (Hospital Outpatient Prospective Payment System – HOPPS) et les centres de chirurgie ambulatoire (Ambulatory Surgery Center – ASC) pour l'année civile 2026. Dans la règle finale, CMS a attribué le code CPT 64568, utilisé pour tous les implants de stimulation du nerf hypoglosse (HGNS) Genio, à la classification de paiement ambulatoire pour les nouvelles technologies (Ambulatory Payment Classification – APC) 1580.

À compter du 1er janvier 2026, le remboursement des services ambulatoires hospitaliers (HOPD) pour le code CPT 64568 passera à environ 45 000 dollars, soit une augmentation de 48 % par rapport à 2025. En outre, le remboursement des centres de chirurgie ambulatoire (ASC) passera à 42 373 dollars, soit une augmentation de 58 % par rapport à 2025.

Ces mises à jour s'appliquent de manière uniforme à toutes les procédures facturées sous le code CPT 64568, y compris Genio®, et renforcent les bases économiques qui soutiennent l'adoption de cette thérapie dans les services ambulatoires des hôpitaux et les centres chirurgicaux ambulatoires aux États–Unis. Grâce à la décision du CMS, Genio® aborde l'année 2026 avec un cadre de remboursement plus solide qui devrait favoriser une adoption plus large, une augmentation du nombre de procédures et une expansion dans les établissements fortement dépendants de Medicare.

La procédure à incision unique de Genio® est parfaitement adaptée à l'environnement des centres de chirurgie ambulatoire (ASC), et l'augmentation significative des paiements versés à ces centres crée de nouvelles opportunités pour l'expansion des traitements et la diversification des lieux de soins.

“La décision de CMS d'augmenter considérablement le remboursement pour le CPT 64568 renforce la reconnaissance croissante de la stimulation du nerf hypoglosse comme traitement de grande valeur pour l'apnée obstructive du sommeil,” a commenté Olivier Taelman, Chief Executive Officer de Nyxoah.“ Les nouveaux tarifs créent un environnement plus favorable à l'élargissement de l'accès à notre traitement Genio dans les hôpitaux ambulatoires et les centres de chirurgie ambulatoire.”

À propos de Nyxoah
Nyxoah opère dans le secteur des technologies médicales. Elle se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). La principale solution de Nyxoah est le système Genio^®, une thérapie de neurostimulation du nerf hypoglosse sans sonde et sans batterie qui a reçu le marquage CE, centrée sur le patient et destinée à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS), le trouble respiratoire du sommeil le plus courant au monde. Ce dernier est associé à un risque accru de mortalité et des comorbidités, dont les maladies cardiovasculaires. La visions de Nyxoah est que les patients souffrant de SAOS doivent pouvoir profiter de nuits réparatrices et vivre pleinement leur vie.

À la suite de la finalisation probante de l’étude BLAST OSA, le système Genio^® a reçu le marquage européen CE en 2019. Nyxoah a réalisé avec succès deux IPO : l’une sur Euronext Bruxelles en septembre 2020 et l’autre sur le NASDAQ en juillet 2021. Grâce aux résultats positifs de l'étude BETTER SLEEP, Nyxoah a reçu le marquage CE pour l’extension de ses indications thérapeutiques aux patients souffrant de collapsus concentrique complet (CCC), pour lesquels les thérapies concurrentes sont actuellement contre–indiquées. En outre, la Société a annoncé les résultats positifs de l'étude pivot DREAM IDE et l'obtention de l'autorisation de la FDA pour un sous–groupe de patients adultes atteints d'AOS modérée à sévère avec un IAH supérieur ou égal à 15 et inférieur ou égal à 65.

Pour plus d’informations, visitez www.nyxoah.com

Attention – marquage CE depuis 2019. Approuvé par la FDA en août 2025 en tant que dispositif disponible uniquement sur prescription médicale.

DÉCLARATIONS PROSPECTIVES
Certaines déclarations, convictions et opinions contenues dans le présent communiqué de presse sont prospectives et reflètent les attentes actuelles de la Société ou, le cas échéant, de ses administrateurs ou de sa direction concernant concernant la clôture du placement privé, l'offre directe enregistrée et le financement par obligation convertible, le système Genio®; les études cliniques prévues et en cours sur le système Genio®; les avantages potentiels du système Genio®; les objectifs de Nyxoah en matière de développement, de parcours réglementaire et d'utilisation potentielle du système Genio® ; la stratégie de commercialisation de la Société et son entrée sur le marché américain ; et les résultats d'exploitation, la situation financière, la liquidité, les performances, les perspectives, la croissance et les stratégies de la Société. De par leur nature, les déclarations prospectives comportent un certain nombre de risques, d'incertitudes, d'hypothèses et d'autres facteurs qui pourraient faire en sorte que les résultats ou événements réels diffèrent sensiblement de ceux exprimés ou sous–entendus dans les déclarations prospectives. Ces risques, incertitudes, hypothèses et facteurs pourraient avoir une incidence défavorable sur les résultats et les effets financiers des plans et événements décrits dans le présent document. En outre, ces risques et incertitudes comprennent, sans s'y limiter, la satisfaction des conditions requises pour la clôture de chacun du placement privé, de l'offre directe enregistrée et du financement par obligation convertible, ainsi que la réalisation des clôtures respectives, les risques et incertitudes énoncés dans la section « Risk Factors » du Annual Report on Form 20–F de la Société pour l'exercice clos le 31 décembre 2024, déposé auprès de la Securities and Exchange Commission (« SEC ») le 20 mars 2025, et dans les rapports ultérieurs que la Société dépose auprès de la SEC. Une multitude de facteurs, y compris, mais sans s'y limiter, les changements dans la demande, la concurrence et la technologie, peuvent faire en sorte que les événements, les performances ou les résultats réels diffèrent considérablement de toute évolution prévue. Les déclarations prospectives contenues dans le présent communiqué de presse concernant les tendances ou les activités passées ne constituent pas des garanties de performances futures et ne doivent pas être considérées comme une indication que ces tendances ou activités se poursuivront à l'avenir. En outre, même si les résultats ou développements réels sont conformes aux déclarations prospectives contenues dans le présent communiqué de presse, ces résultats ou développements ne sont pas nécessairement indicatifs des résultats ou développements futurs. Aucune déclaration ni garantie n'est faite quant à l'exactitude ou à l'équité de ces déclarations prospectives. Par conséquent, la Société décline expressément toute obligation ou engagement de publier des mises à jour ou des révisions des déclarations prospectives contenues dans le présent communiqué de presse à la suite d'un changement dans les attentes ou d'un changement dans les événements, les conditions, les hypothèses ou les circonstances sur lesquels ces déclarations prospectives sont fondées, sauf si la loi ou la réglementation l'exige expressément. Ni la Société, ni ses conseillers ou représentants, ni aucune de ses filiales, ni aucun des dirigeants ou employés de ces personnes ne garantissent que les hypothèses sous–jacentes à ces déclarations prospectives sont exemptes d'erreurs, et n'acceptent aucune responsabilité quant à l'exactitude future des déclarations prospectives contenues dans le présent communiqué de presse ou à la réalisation effective des développements prévus. Vous ne devez pas vous fier indûment aux déclarations prospectives, qui ne sont valables qu'à la date du présent communiqué de presse.

Contacts :

Nyxoah
John Landry, CFO
[email protected]

Rémi Renard
Chief Investor Relations & Corporate Communication Officer
[email protected]

Pièce jointe

• FRENCH_2026 CMS Final Payment Rule_FINAL

GLOBENEWSWIRE (Distribution ID 1001141004)

REGULATED INFORMATION

Information on the total number of voting rights and shares

Mont–Saint–Guibert (Belgium), November 20, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares.

• Share capital: EUR 6.504.688,76
• Total number of securities carrying voting rights: 43,026,460 (all ordinary shares)
• Total number of voting rights (= denominator): 43,026,460 (all relating to ordinary shares)
• Number of rights to subscribe to securities carrying voting rights not yet issued: 3,258,819 (all granted subscription rights; this number excludes 692,677 subscription rights that were issued but not yet granted)

*

* *

Contact:
Nyxoah
John Landry, CFO
[email protected]

Attachment

• 2025 11 20 – Press release – Number of shares (ENG)

GLOBENEWSWIRE (Distribution ID 1001140138)

INFORMATION RÉGLEMENTÉE

Informations sur le nombre total de droits de vote et d'actions

Mont–Saint–Guibert (Belgique), le 20 novembre 2025, 22:30h CET / 16:30h ET – Conformément à l'article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publie les informations ci–dessous suite à l'émission de nouvelles actions.

• Capital: EUR 6.504.688,76
• Nombre total de titres avec droits de vote: 43.026.460 (tous des actions ordinaires)
• Nombre total de droits de vote (= dénominateur): 43.026.460 (tous liés aux actions ordinaires)
• Nombre de droits de souscrire à des titres avec droits de vote non encore émis: 3.258.819 (tous des droits de souscription octroyés; ce nombre exclut 692.677 droits de souscription émis mais pas encore octroyés)

*

* *

Contact:
Nyxoah
John Landry, CFO
[email protected]

Pièce jointe

• 2025 11 20 – Press release – Number of shares (FR)

GLOBENEWSWIRE (Distribution ID 1001140138)

INSIDE INFORMATION
REGULATED INFORMATION

Correction and Replacement

Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio

Financings are comprised of equity investments, including from Cochlear, Resmed and Nyxoah’s Chairman and Management, and a convertible bond.

This press release replaces the press release issued on November 13, 2025, at 10:11 pm CET / 4:11 pm ET in order to replace and correct the gross proceeds of the private placement and registered direct offering and to add a paragraph under the header “Additional Information” (statutory auditor’s assessment)

Mont–Saint–Guibert, Belgium – November 14, 2025, 1:30 am CET / November 13, 7:30 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA) through neuromodulation, today announced a €17 million private placement of equity, a U.S. $5.6 million registered direct offering, combined with a convertible bond financing of up to €45 million.

The private placement consists of the issuance of 4,265,714 new ordinary shares at a subscription price per share of €4.00 (approximately U.S. $4.6304 at current exchange rates) with gross proceeds totaling €17 million (approximately U.S. $20 million at current exchange rates). The closing of the private placement is expected to occur on or about November 17, 2025, subject to customary closing conditions. Degroof Petercam acted as the sole book runner for this private placement.

The ordinary shares are being sold in a private placement and have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Additionally, the registered direct offering consists of the issuance of 1,215,964 new ordinary shares at a price per share of U.S. $4.6304 with gross proceeds totaling approximately U.S. $5.6 million. The closing of the registered direct offering is expected to occur on or about November 18, 2025, subject to customary closing conditions.

The registered direct offering is being made pursuant to an effective shelf registration statement on Form F–3 (File No. 333– 268955) which was declared effective by the Securities and Exchange Commission (the “SEC”) on January 6, 2023. The offering is being made only by means of a prospectus which is part of the effective registration statement. A prospectus supplement and the accompanying base prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov.

Additionally, the Company entered into a subscription agreement with an international financial services firm for the issuance of convertible bonds for an aggregate maximum principal amount of up to €45 million (approximately U.S. $52 million at current exchange rate). The financing consists of a first tranche of up to €22.5 million with an option to issue a second tranche of €22.5 million at Nyxoah’s discretion, during the 30 days beginning seven months from the closing date subject to certain conditions. The closing for the first tranche of bonds is expected to occur in December 2025, subject to customary closing conditions. The first tranche of bonds will be issued at 92 per cent of their principal amount and carry an interest rate of 6.5 per cent per annum, payable every quarter in arrears. The bonds have a three–year maturity from issuance with quarterly amortization payments of principal and interest. The default conversion price for the first tranche of bonds, which can be modified on a downward basis, shall be equal to EUR 5.00, which represents 125 per cent of the placement price of the Shares being issued pursuant to the private placement.

The net proceeds from the convertible bonds together with the net proceeds of the private placement, will be used (i) to support commercialization activities in the United States and advance the commercialization of the Genio system in the Company’s initial target markets outside the United States; (ii) to continue gathering clinical data and to support physician–initiated clinical research projects related to OSA patient treatments; (iii) to further finance research and development activities related to Genio system upgrades, re–designing the Company’s products for manufacturability and cost reduction initiatives; (iv) to continue to build a pipeline of new technologies and explore potential collaboration opportunities in the field of monitoring and diagnostics for OSA; and (v) for other general corporate purposes, including, but not limited to, working capital, capital expenditures, investments, acquisitions, should the Company choose to pursue any, and collaborations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription–only device.

ADDITIONAL INFORMATION

The following information is provided pursuant to article 7:97 of the Belgian Code on companies and associations. The investors that have participated in the private placement include, among others, (either directly or through entities controlled by them) Robert Taub, who is the chairman of the board of directors, Jürgen Hambrecht and Daniel Wildman (permanent representative of Wildman Ventures LLC), who are independent directors, Olivier Taelman, CEO and director of the Company, John Landry, CFO of the Company and Scott Holstine, Chief Commercial Officer of the Company. Together, these investors have subscribed to 356,250 new shares for EUR 1.425 million in gross proceeds at an issue price equal to EUR 4.00.

As Robert Taub, Jürgen Hambrecht, Daniel Wildman, Olivier Taelman, John Landry and Scott Holstine qualify as related parties of the Company, the board of directors applied the related parties procedure of article 7:97 of the Belgian Code on companies and associations in connection with the participation of the aforementioned related parties in the private placement. Within the context of the aforementioned procedure, prior to resolving on the private placement, a committee of three independent directors of the Company consisting of Rita Johnson–Mills, Virginia Kirby and Kevin Rakin (the “Committee”) issued an advice to the board of directors in which the Committee assessed the participation of the six aforementioned investors in the private placement. In its advice to the board of directors, the Committee concluded the following: “Based on the information provided, the Committee considers that the proposed Transaction is in line with the strategy pursued by the Company, will be done on market terms, and is unlikely to lead to disadvantages for the Company and its shareholders (in terms of dilution) that are not sufficiently compensated by the advantages that the Transaction offers the Company”.

The Company’s board of directors approved the principle of the private placement and did not deviate from the Committee's advice.

The Company’s statutory auditor's assessment of the Committee's advice and the minutes of the meeting of the Company’s board of directors, is as follows: “Based on our assessment, nothing has come to our attention that causes us to believe that the financial and accounting data included in the opinion of the committee of independent directors dated 13 November 2025 and in the minutes of the board of directors dated 13 November 2025, justifying the proposed transaction, are not fair and adequate in all material respects in light of the information available to it in connection with its engagement. Our assignment was carried out solely within the framework of the provisions of Article 7:97 of the Companies and Associations Code and our report cannot therefore be used in any other context.”

IMPORTANT INFORMATION

THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS FOR GENERAL INFORMATION ONLY AND DOES NOT FORM PART OF ANY OFFER TO SELL OR PURCHASE, OR THE SOLICITATION OF ANY OFFER TO SELL OR PURCHASE, ANY SECURITIES. THE DISTRIBUTION OF THIS ANNOUNCEMENT AND THE OFFER, SUBSCRIPTION, SALE AND PURCHASE OF SECURITIES DESCRIBED IN THIS ANNOUNCEMENT IN CERTAIN JURISDICTIONS MAY BE RESTRICTED BY LAW. ANY PERSONS READING THIS ANNOUNCEMENT SHOULD INFORM THEMSELVES OF AND OBSERVE ANY SUCH RESTRICTIONS.

Forward–looking statements

Certain statements, beliefs and opinions in this press release are forward–looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the closings of the private placement, the registered direct offering and the convertible bond financing; the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward–looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward–looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the satisfaction of the closing conditions required for the closing of each of the private placement, the registered direct offering and the convertible bond financing and the consummation of the respective closings, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20–F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward–looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward–looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward–looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward–looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward– looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward–looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward–looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward–looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah
John Landry, CFO
[email protected]

Attachment

• Financing PR – correction (final)

GLOBENEWSWIRE (Distribution ID 1001138789)

INSIDE INFORMATION
REGULATED INFORMATION

Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio

Financings are comprised of equity investments, including from Cochlear, Resmed and Nyxoah’s Chairman and Management, and a convertible bond.

Mont–Saint–Guibert, Belgium – November 13, 2025, 2025, 10:11pm CET / 4:11 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA) through neuromodulation, today announced a €22 million private placement of equity, a U.S. $5.6 million registered direct offering, and a €17 million registered direct offering combined with a convertible bond financing of up to €45 million.

The private placement consists of the issuance of 5,481,678 new ordinary shares at a subscription price per share of €4.00 (approximately U.S. $4.6304 at current exchange rates) with gross proceeds totaling €22 million (approximately U.S. $25 million at current exchange rates). The closing of the private placement is expected to occur on or about November 17, 2025, subject to customary closing conditions. Degroof Petercam acted as the sole book runner for this private placement.

The ordinary shares are being sold in a private placement and have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Additionally, the registered direct offering consists of the issuance of 1,215,964 new ordinary shares at a price per share of U.S. $4.6304 with gross proceeds totaling approximately U.S. $5,6 million. The closing of the registered direct offering is expected to occur on or about November 18, 2025, subject to customary closing conditions.

The registered direct offering is being made pursuant to an effective shelf registration statement on Form F–3 (File No. 333– 268955) which was declared effective by the Securities and Exchange Commission (the “SEC”) on January 6, 2023. The offering is being made only by means of a prospectus which is part of the effective registration statement. A prospectus supplement and the accompanying base prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov.

Additionally, the Company entered into a subscription agreement with an international financial services firm for the issuance of convertible bonds for an aggregate maximum principal amount of up to €45 million (approximately U.S. $52 million at current exchange rate). The financing consists of a first tranche of up to €22.5 million with an option to issue a second tranche of €22.5 million at Nyxoah’s discretion, during the 30 days beginning seven months from the closing date subject to certain conditions. The closing for the first tranche of bonds is expected to occur in December 2025, subject to customary closing conditions. The first tranche of bonds will be issued at 92 per cent of their principal amount and carry an interest rate of 6.5 per cent per annum, payable every quarter in arrears. The bonds have a three–year maturity from issuance with quarterly amortization payments of principal and interest. The default conversion price for the first tranche of bonds, which can be modified on a downward basis, shall be equal to EUR 5.00, which represents 125 per cent of the placement price of the Shares being issued pursuant to the private placement.

The net proceeds from the convertible bonds together with the net proceeds of the private placement, will be used (i) to support commercialization activities in the United States and advance the commercialization of the Genio system in the Company’s initial target markets outside the United States; (ii) to continue gathering clinical data and to support physician–initiated clinical research projects related to OSA patient treatments; (iii) to further finance research and development activities related to Genio system upgrades, re–designing the Company’s products for manufacturability and cost reduction initiatives; (iv) to continue to build a pipeline of new technologies and explore potential collaboration opportunities in the field of monitoring and diagnostics for OSA; and (v) for other general corporate purposes, including, but not limited to, working capital, capital expenditures, investments, acquisitions, should the Company choose to pursue any, and collaborations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription–only device.

ADDITIONAL INFORMATION

The following information is provided pursuant to article 7:97 of the Belgian Code on companies and associations. The investors that have participated in the private placement include, among others, (either directly or through entities controlled by them) Robert Taub, who is the chairman of the board of directors, Jürgen Hambrecht and Daniel Wildman (permanent representative of Wildman Ventures LLC), who are independent directors, Olivier Taelman, CEO and director of the Company, John Landry, CFO of the Company and Scott Holstine, Chief Commercial Officer of the Company. Together, these investors have subscribed to 356,250 new shares for EUR 1.425 million in gross proceeds at an issue price equal to EUR 4.00.

As Robert Taub, Jürgen Hambrecht, Daniel Wildman, Olivier Taelman, John Landry and Scott Holstine qualify as related parties of the Company, the board of directors applied the related parties procedure of article 7:97 of the Belgian Code on companies and associations in connection with the participation of the aforementioned related parties in the private placement. Within the context of the aforementioned procedure, prior to resolving on the private placement, a committee of three independent directors of the Company consisting of Rita Johnson–Mills, Virginia Kirby and Kevin Rakin (the “Committee”) issued an advice to the board of directors in which the Committee assessed the participation of the six aforementioned investors in the private placement. In its advice to the board of directors, the Committee concluded the following: “Based on the information provided, the Committee considers that the proposed Transaction is in line with the strategy pursued by the Company, will be done on market terms, and is unlikely to lead to disadvantages for the Company and its shareholders (in terms of dilution) that are not sufficiently compensated by the advantages that the Transaction offers the Company”.

The Company’s board of directors approved the principle of the private placement and did not deviate from the Committee's advice.

IMPORTANT INFORMATION

THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS FOR GENERAL INFORMATION ONLY AND DOES NOT FORM PART OF ANY OFFER TO SELL OR PURCHASE, OR THE SOLICITATION OF ANY OFFER TO SELL OR PURCHASE, ANY SECURITIES. THE DISTRIBUTION OF THIS ANNOUNCEMENT AND THE OFFER, SUBSCRIPTION, SALE AND PURCHASE OF SECURITIES DESCRIBED IN THIS ANNOUNCEMENT IN CERTAIN JURISDICTIONS MAY BE RESTRICTED BY LAW. ANY PERSONS READING THIS ANNOUNCEMENT SHOULD INFORM THEMSELVES OF AND OBSERVE ANY SUCH RESTRICTIONS.

Forward–looking statements

Certain statements, beliefs and opinions in this press release are forward–looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the closings of the private placement, the registered direct offering and the convertible bond financing; the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward–looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward–looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the satisfaction of the closing conditions required for the closing of each of the private placement, the registered direct offering and the convertible bond financing and the consummation of the respective closings, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20–F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward–looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward–looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward–looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward–looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward– looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward–looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward–looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward–looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah
John Landry, CFO
[email protected]

Attachment

• Financing PR

GLOBENEWSWIRE (Distribution ID 1001138771)